Enhanced S-Cone Syndrome

Enhanced S-Cone Syndrome (ESCS), which includes a condition sometimes called Goldmann-Favre syndrome, is a rare genetic eye disorder that affects the retina, the light-sensitive tissue at the back of the eye. In a healthy eye, there are two main types of light-detecting cells: rods, which help us see in the dark, and cones, which help us see colors and fine details. People with ESCS are born with a unique imbalance in these cells; they have no working rod cells and an unusually high number of a specific type of cone cell called the "S-cone" (which detects blue light). Because they lack rod cells, the most common and earliest symptom of ESCS is night blindness, meaning patients have significant difficulty seeing in low light or dark environments, often starting in early childhood. Other symptoms can include increased sensitivity to blue light, decreased central vision, and sometimes seeing flashes of light. The condition is progressive, meaning vision can slowly worsen over time, but the severity varies greatly from person to person. Some people maintain good vision for a long time, while others may experience more significant vision loss. Currently, there is no cure for ESCS, but regular eye exams are crucial. Eye doctors can monitor the condition and treat specific complications that may arise, such as swelling in the center of the retina (macular schisis) or abnormal blood vessel growth. Treatment might include special eye drops, oral medications, or sometimes injections in the eye. Genetic testing and counseling are also recommended to help families understand the condition and how it is inherited.

Condition category: Retinal Dystrophy

Prevalence: Less than 1 in 1,000,000

Inheritance patterns: Autosomal Recessive

Age of onset: Birth to early childhood

Clinical overview: Note: Enhanced S-Cone Syndrome (ESCS) and Goldmann-Favre Syndrome are both caused by NR2E3 mutations and represent a spectrum. Goldmann-Favre is the more severe phenotype. See also the Goldmann-Favre Syndrome entry. Enhanced S-Cone Syndrome (ESCS), which encompasses the clinical entity historically known as Goldmann-Favre syndrome, is a rare, progressive inherited retinal dystrophy. It is uniquely characterized by an abnormal development of retinal photoreceptors, resulting in an overabundance of S-cones (short-wavelength or blue cones) and a complete lack of functional rod photoreceptors. This distinct cellular composition leads to a specific clinical phenotype that differentiates it from other retinal degenerations. The condition is primarily inherited in an autosomal recessive manner and is most commonly caused by mutations in the NR2E3 gene, and less frequently in the NRL gene. These genes encode transcription factors critical for normal photoreceptor differentiation. The disruption of this process leads to the characteristic clinical features, which include early-onset nyctalopia (night blindness), increased sensitivity to blue light, and variable degrees of visual acuity loss. Clinically, ESCS is identified by pathognomonic electroretinogram (ERG) findings and characteristic fundus changes, such as nummular pigmentary deposits and macular schisis. The disease exhibits significant phenotypic variability, ranging from mild visual impairment to severe vision loss. The relevant OMIM numbers for ESCS and its associated gene are 268100 (Phenotype) and 604485 (NR2E3 Gene). The Orphanet identifier for Goldmann-Favre syndrome/ESCS is ORPHA:53540.

Patient and family guide: Enhanced S-Cone Syndrome (ESCS), which includes a condition sometimes called Goldmann-Favre syndrome, is a rare genetic eye disorder that affects the retina, the light-sensitive tissue at the back of the eye. In a healthy eye, there are two main types of light-detecting cells: rods, which help us see in the dark, and cones, which help us see colors and fine details. People with ESCS are born with a unique imbalance in these cells; they have no working rod cells and an unusually high number of a specific type of cone cell called the "S-cone" (which detects blue light). Because they lack rod cells, the most common and earliest symptom of ESCS is night blindness, meaning patients have significant difficulty seeing in low light or dark environments, often starting in early childhood. Other symptoms can include increased sensitivity to blue light, decreased central vision, and sometimes seeing flashes of light. The condition is progressive, meaning vision can slowly worsen over time, but the severity varies greatly from person to person. Some people maintain good vision for a long time, while others may experience more significant vision loss. Currently, there is no cure for ESCS, but regular eye exams are crucial. Eye doctors can monitor the condition and treat specific complications that may arise, such as swelling in the center of the retina (macular schisis) or abnormal blood vessel growth. Treatment might include special eye drops, oral medications, or sometimes injections in the eye. Genetic testing and counseling are also recommended to help families understand the condition and how it is inherited.

Symptoms and clinical features: The clinical presentation of Enhanced S-Cone Syndrome (ESCS) is characterized by early-onset visual symptoms, primarily due to the congenital absence of rod photoreceptors. In the early stages, typically within the first decade of life, the most prominent symptom is nyctalopia (night blindness). Children may also present with refractive errors, most commonly hypermetropia (farsightedness), and sometimes accommodative esotropia or nystagmus. Increased sensitivity to blue light is a unique feature of this condition, stemming from the overabundance of S-cones. As the disease progresses into the intermediate stages, patients may experience a gradual decline in visual acuity. Color vision is typically diminished, although the tritan (blue-yellow) axis is often preserved. Patients may also report photopsia (flashes of light). During this stage, characteristic fundus changes become more apparent, including nummular pigmentary deposits along the vascular arcades and the development of macular schisis (cystic changes in the macula), which can further impair central vision. In the advanced stages of ESCS, visual acuity can be profoundly impaired, with a significant portion of patients progressing to legal blindness. The macular schisis cavities may involute, leading to advanced macular atrophy. Additionally, patients are at risk of developing subretinal fibrosis secondary to choroidal neovascularization, which can cause sudden and severe vision loss. The visual field may also become progressively constricted as the retinal degeneration advances.

Molecular pathology: Enhanced S-Cone Syndrome is caused by mutations that disrupt the normal development and differentiation of retinal photoreceptors. The primary gene involved, NR2E3, encodes a photoreceptor-specific orphan nuclear receptor that acts as a transcription factor. This protein is normally expressed in the outer nuclear layer of the human retina and plays a crucial role in cell fate determination during retinal development. The normal function of the NR2E3 transcription factor is to promote the development of rod photoreceptors and to suppress the expression of cone-specific genes, particularly those related to S-cones (short-wavelength or blue cones). It works in concert with other transcription factors, such as NRL, which directly regulates NR2E3 expression. When mutations occur in the NR2E3 gene (or the upstream NRL gene), this regulatory mechanism is disrupted. The loss of functional NR2E3 protein leads to a failure in rod photoreceptor differentiation and an inability to suppress S-cone development. Consequently, the default pathway of photoreceptor differentiation is altered, resulting in an over-expansion and overabundance of S-cone photoreceptors and a complete lack of functional rod photoreceptors. This abnormal cellular composition of the retina is the fundamental pathological basis for the clinical features of ESCS.

Genetics: Enhanced S-Cone Syndrome is primarily inherited in an autosomal recessive pattern. The most common causative gene is NR2E3 (Nuclear Receptor Subfamily 2, Group E, Member 3), located on chromosome 15q23. There are over 30 known pathogenic mutations in the NR2E3 gene associated with ESCS. In the United States, the NR2E3 c.119-2A>C splice site variant is the most frequently observed mutation. A unique autosomal dominant form of the disease has also been linked to a specific missense variant in the NR2E3 gene. In rare cases, mutations in the NRL (Neural Retina Leucine zipper) gene have been identified as the cause of ESCS. The NRL gene acts upstream of NR2E3, directly regulating its expression. Therefore, mutations in NRL can lead to the ESCS phenotype by disrupting the normal function and expression of the NR2E3 transcription factor. Genotype-phenotype correlations in ESCS are complex and variable. Even among patients with the same NR2E3 mutations, there can be significant clinical variability in disease severity, visual acuity, and the extent of retinal degeneration. Some NR2E3 mutations are also implicated in other retinal dystrophies, including autosomal dominant retinitis pigmentosa, Goldmann-Favre syndrome, and clumped pigmentary retinal degeneration, highlighting the genetic heterogeneity and phenotypic spectrum associated with this gene.

Diagnostic evaluation: Clinical diagnosis of Enhanced S-Cone Syndrome (ESCS) relies heavily on electrophysiological testing. The full-field electroretinogram (ERG) is pathognomonic, demonstrating an absent rod response on a low-intensity dark-adapted stimulus. Both scotopic and photopic ERG waveforms are remarkably similar. The 30 Hz flicker response is typically delayed and of low amplitude. A specific S-cone ERG, elicited using a blue wavelength on an orange background to suppress red and green cones, reveals a greater than normal S-cone response, which is the hallmark of the disease. Fundus examination reveals characteristic findings, most notably nummular pigmentary changes along the vascular arcades, which are present in approximately 85% of patients. Other findings include macular schisis (cystic changes in the macula), torpedo-like atrophic lesions, and subretinal yellow-white lesions in the posterior pole. Optical coherence tomography (OCT) is crucial for identifying foveal schisis, cystoid macular edema, and loss of outer retinal layers. Fundus autofluorescence typically shows decreased autofluorescence in the peripheral retina with relatively increased autofluorescence in the macula, and hyperautofluorescent yellow-white lesions. Genetic testing for pathogenic variants in the NR2E3 gene (and rarely the NRL gene) confirms the diagnosis. The differential diagnosis includes other causes of childhood nyctalopia and retinal dystrophies such as congenital stationary night blindness, retinitis pigmentosa, fundus albipunctatus, and Goldmann-Favre syndrome, which is considered to be on the same phenotypic spectrum as ESCS. Nummular pigmentary deposits can also be seen in Bardet-Biedl syndrome and CRB1-associated early-onset severe retinal dystrophy.

Differential diagnosis: Differential diagnosis of enhanced S-cone syndrome includes: (1) Goldmann-Favre syndrome — same genetic basis (NR2E3), with more prominent retinoschisis and vitreous changes. (2) Retinitis pigmentosa — similar night blindness but without enhanced S-cone response on ERG. (3) X-linked retinoschisis — macular schisis but normal S-cone function; RS1 mutations. (4) Congenital stationary night blindness — nonprogressive, different ERG pattern. (5) Clumped pigmentary retinal degeneration — distinctive fundus appearance with clumped pigment deposits.

Natural history: Enhanced S-Cone Syndrome is a slowly progressive retinal degeneration. The onset of symptoms typically occurs in early childhood, often within the first decade of life, with nyctalopia (night blindness) being the most common initial presentation. The night blindness is generally present from birth due to the congenital absence of functional rod photoreceptors. The progression of the disease exhibits significant clinical variability. Some patients experience extensive retinal degeneration and a severe decline in visual function over time, while others show very little progression and maintain excellent visual acuity for decades. The development of complications such as macular schisis or choroidal neovascularization can significantly impact the rate of visual decline and overall prognosis. Long-term follow-up studies have shown that while the disease is progressive, the rate of change can be slow. Patients require lifelong monitoring to manage complications and assess visual function. Despite the visual impairment, ESCS is an isolated ocular condition with no systemic associations, and patients have a normal life expectancy.

Management and treatment research: ### Current Management and Standard of Care Enhanced S-cone syndrome (ESCS) is most often caused by disease-causing variants in the **NR2E3** gene. Management focuses on monitoring retinal health, maximizing remaining vision, and treating complications that may affect central vision. - **Regular retinal monitoring:** A retinal specialist may use eye examinations, visual-field testing, retinal photographs, and optical coherence tomography (OCT). OCT is a noninvasive scan that shows the retina’s layers and can identify macular schisis—splitting or cyst-like spaces in the macula, the part of the retina responsible for detailed central vision. - **Glasses or contact lenses:** Correcting refractive errors can improve daily vision. Hyperopia (farsightedness) may occur in ESCS. - **Low-vision rehabilitation:** Low-vision services can provide magnifiers, electronic reading tools, lighting and contrast strategies, assistive technology, orientation and mobility training, and school or workplace accommodations. - **Genetic testing and counseling:** Genetic testing can confirm an **NR2E3**-related diagnosis, clarify inheritance in a family, and help identify research registries or future study opportunities. ### Treatment of Retinal Complications Some retinal complications associated with ESCS may be treatable. A retinal specialist can determine whether treatment is appropriate and monitor response over time. - **Macular schisis or cystic macular changes:** Carbonic anhydrase inhibitors may be considered for some people with retinal fluid or cyst-like changes. These medicines may include dorzolamide eye drops or oral acetazolamide. OCT can help monitor retinal changes. - **Choroidal neovascularization (CNV):** CNV is the growth of abnormal blood vessels in or beneath the retina that can threaten central vision. If CNV develops, treatment may include injections of anti-VEGF medicines, such as bevacizumab or ranibizumab. Anti-VEGF medicines block a signal involved in abnormal blood-vessel growth. ### Approved Therapies There are currently no approved treatments that correct the underlying genetic cause of ESCS or specifically treat **NR2E3**-related retinal disease. There are no approved gene therapies for ESCS. ### Investigational Therapies There are no ESCS-specific treatment candidates in the current treatment pipeline. Research in inherited retinal diseases includes gene-based approaches intended to address disease-causing variants or preserve remaining retinal cells. Laboratory research has explored gene-editing approaches for certain **NR2E3** variants in patient-derived cells. These studies are preclinical, meaning they have not been established as treatments in people. **OCU400** is being studied in people with retinitis pigmentosa and Leber congenital amaurosis in a Phase 1/2 study (NCT05203939). The study is active but not recruiting. It is not an ESCS-specific study, and an ESCS diagnosis does not indicate eligibility. ### Clinical Trial Participation Because ESCS is rare, registries can be an important way to support research and learn about future study opportunities. The Inherited Retinal Degenerative Disease Registry (NCT02435940) is recruiting and collects information about inherited retinal diagnoses, genetic findings, vision, and disease progression. A retinal specialist, genetic counselor, or registry study team can help individuals and families discuss whether registry participation is appropriate.

Outlook: The prognosis for visual outcomes in Enhanced S-Cone Syndrome is highly variable. The disease is characterized as a slowly progressive retinal degeneration. While some patients experience a significant decline in visual acuity and severe vision loss, others may show minimal progression and maintain excellent visual acuity throughout their lives. The presence and severity of complications, particularly macular schisis and choroidal neovascularization, are major factors that negatively affect visual prognosis. Quality of life considerations primarily revolve around managing visual impairment. Night blindness is a constant feature from birth, requiring adaptations for low-light environments. Patients may also need refractive correction for hypermetropia and support services for visual rehabilitation if significant vision loss occurs. Regular ophthalmic monitoring is essential to detect and treat complications early, which can help preserve vision and improve the quality of life for affected individuals.

Epidemiology: Enhanced S-Cone Syndrome is a rare inherited retinal dystrophy. The exact prevalence is not well-established, but it is considered very rare, with fewer than 100 cases reported in some literature, though studies have identified associated gene mutations worldwide. There are no specific geographic or ethnic variations consistently reported, although certain mutations may be more common in specific populations, such as the NR2E3 c.119-2A>C variant in the United States. The condition affects both males and females equally, consistent with its autosomal recessive inheritance pattern. There are no known systemic associations, and patients have a normal life expectancy.

Selected references: 1. Haider NB, et al., Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet, 2000. PMID: 10655068 2. de Carvalho ER, et al., Enhanced S-Cone Syndrome: Spectrum of Clinical, Imaging, Electrophysiologic, and Genetic Findings in a Retrospective Case Series of 56 Patients. Ophthalmol Retina, 2021. PMID: 32679203 3. Yzer S, et al., Expanded clinical spectrum of enhanced S-cone syndrome. JAMA Ophthalmol, 2013. PMID: 23868099 4. Littink KW, et al., Autosomal Recessive NRL Mutations in Patients with Enhanced S-Cone Syndrome. Genes (Basel), 2018. PMID: 29385754 5. Jacobson SG, et al., SWS (blue) cone hypersensitivity in a newly identified retinal degeneration. Invest Ophthalmol Vis Sci, 1990. PMID: 2335435 6. Khan AO, et al., The enhanced S-cone syndrome in children. BMJ Case Rep, 2009. PMID: 21686658